Oral Pathogens and Dendritic Cell Subsets

口腔病原体和树突状细胞亚群

基本信息

项目摘要

DESCRIPTION (Adapted from the Investigator's Abstract): The Principal Investigator has proposed a novel overall hypothesis and approach to understanding the pathophysiology of adult periodontitis (AP), one of the most common of diseases that afflict the US population. While mortality of the dentition is the most familiar outcome of AP, its links with other more severe diseases, including coronary artery disease, respiratory diseases and pre-term labor cannot be ignored. These investigators have called attention to the many intriguing parallels between AP and contact hypersensitivity (CHS). CHS is among the most common of dermatoses that afflicts mankind and one of the most intensively studied of in vivo immune responses. Both AP and CHS target the host integument (gingiva or skin) and appear to involve the activation and sensitization of similar subsets of antigen capture and presenting cells, the dendritic cells. Dendritic cells have been termed "Nature's adjuvant," being more efficient at antigen-presentation than macrophages or B cells and the only antigen-presenting cells (APCs) than can stimulate naive T cells to proliferate. This immunostimulatory capacity can also have detrimental effects for the host, as typified by contact hypersensitivity (CHS) responses. Both AP and CHS involve a predominantly destructive T cell response mediated by both regulatory and effector T cells. These investigators have shown that Porphyromonas gingivalis is a unique pathogen in this regard, able to infect, sensitize, and activate dendritic cells in vitro and likely, in situ. Many questions about the role of P. gingivalis-sensitized dendritic cells in AP, however, remain unanswered. The present proposal will definitively establish, using in situ, ex vivo and in vitro approaches, the role of dendritic cells in adult periodontitis, particularly that induced by P. gingivalis. Moreover, these studies will characterize the interactions of P. gingivalis with dendritic cells and will further our knowledge of the pathophysiology of AP as it relates to CHS. Future studies, outside the purview of this proposal, will involve understanding the T cell response to P. gingivalis-activated dendritic cells.
描述(改编自研究者摘要):负责人 研究人员提出了一种新的总体假设和方法, 了解成人牙周炎(AP)的病理生理学, 这是困扰美国人口的常见疾病。虽然死亡率 牙列是AP最常见的结果,它与其他更严重的疾病有关。 疾病,包括冠状动脉疾病、呼吸系统疾病和早产儿 劳动不能忽视。这些调查人员已经引起了许多人的注意, AP和接触性超敏反应(CHS)之间有趣的相似之处。CHS是 其中最常见的皮肤病,折磨人类和一个最 深入研究体内免疫反应。AP和CHS都针对 宿主外皮(牙龈或皮肤),似乎涉及激活, 抗原捕获和呈递细胞的相似亚群的致敏, 树突状细胞树突状细胞被称为“天然佐剂”, 比巨噬细胞或B细胞更有效地呈递抗原, 抗原呈递细胞(APC),可以刺激幼稚T细胞, 增殖。这种免疫刺激能力也可能产生有害影响 对宿主而言,以接触性超敏反应(CHS)为代表。两部AP CHS和CHS涉及由两者介导的主要破坏性T细胞应答, 调节和效应T细胞。这些调查人员已经表明, 牙龈卟啉单胞菌在这方面是一种独特的病原体,能够感染, 致敏,并激活树突状细胞在体外和可能,在原位。许多 关于牙龈卟啉单胞菌致敏的树突状细胞在AP中的作用的问题, 但仍没有得到答复。本提案将明确规定, 使用原位、离体和体外方法,树突状细胞在 成人牙周炎,特别是牙龈卟啉单胞菌引起的牙周炎。此外,委员会认为, 这些研究将描述牙龈卟啉单胞菌与 树突状细胞,并将进一步我们的知识,病理生理学的AP, 它与CHS有关。本建议范围以外的未来研究将 包括理解T细胞对牙龈卟啉单胞菌激活的树突状细胞的反应, 细胞

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER William CUTLER其他文献

CHRISTOPHER William CUTLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER William CUTLER', 18)}}的其他基金

DC exosome therapy to resolve inflammatory bone loss and oral infection
DC外泌体疗法解决炎症性骨质流失和口腔感染
  • 批准号:
    10450633
  • 财政年份:
    2021
  • 资助金额:
    $ 28.6万
  • 项目类别:
Peripheral blood dendritic cells and periodontitis
外周血树突状细胞与牙周炎
  • 批准号:
    8043883
  • 财政年份:
    2010
  • 资助金额:
    $ 28.6万
  • 项目类别:
Peripheral blood dendritic cells and periodontitis
外周血树突状细胞与牙周炎
  • 批准号:
    8388384
  • 财政年份:
    2010
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    8721745
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    8097419
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    8288024
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    7479959
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    7743442
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    6411298
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:
Oral Pathogens and Dendritic Cell Subsets
口腔病原体和树突状细胞亚群
  • 批准号:
    7529884
  • 财政年份:
    2001
  • 资助金额:
    $ 28.6万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 28.6万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 28.6万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 28.6万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 28.6万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了